GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
Summary
To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.
Timeline
- Start
- 2021-02-01
- Primary completion
- 2024-11-19
- Completion
- 2024-11-19
Outcome
Mixed primary results
registry MEAN GLP-1a: -0.7 (Standard Deviation 0.6) score NCT04779697 ↗
registry MEAN Placebo: -0.3 (Standard Deviation 0.4) score NCT04779697 ↗
registry analysis (superiority test); GLP-1a vs Placebo; p < 0.001; ANOVA NCT04779697 ↗
registry MEAN GLP-1a: -0.5 (Standard Deviation 1.7) score NCT04779697 ↗
registry MEAN Placebo: -0.1 (Standard Deviation 1.7) score NCT04779697 ↗
registry analysis (superiority test); GLP-1a vs Placebo; p > 0.27; ANOVA NCT04779697 ↗
registry MEAN GLP-1a: -0.4 (Standard Deviation 1.8) Kcalories NCT04779697 ↗
registry MEAN Placebo: 0.4 (Standard Deviation 2.4) Kcalories NCT04779697 ↗
registry analysis (superiority test); GLP-1a vs Placebo; p < 0.043; ANOVA NCT04779697 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Semaglutide | Peptide | 1.2 mg | — |